clinical trial · NCT05647122
First in Human Study of AZD9592 in Solid Tumors
Advanced Solid TumoursCarcinoma Non-small Cell LungHead and Neck NeoplasmsColorectal NeoplasmsAZD9592Osimertinib5-Fluorouracil (5-FU)LeucovorinBevacizumab
brief summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
started
Dec 21, 2022
primary completion
Aug 3, 2028
completion
Aug 3, 2028
last updated
Jun 11, 2026
official title
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol